Recent Progress on Therapeutic Vaccines for Breast Cancer

Frontiers in Oncology

Xipeng Zhou¹  Baorui Liu¹  Huizi Sha²  Li Xie³  Lianru Zhang³ 

[1] Clinical Cancer Institute of Nanjing University, Nanjing, China;Department of oncology, Yizheng People’s Hospital, Yangzhou, China;;The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University &

关键词: breast cancer;    cancer vaccines;    cancer immunotherapy;    clinical trials;    concurrent therapies;   

DOI  :  10.3389/fonc.2022.905832

来源: DOAJ

【 摘 要 】

Breast cancer remains the most frequently diagnosed malignancy worldwide. Advanced breast cancer is still an incurable disease mainly because of its heterogeneity and limited immunogenicity. The great success of cancer immunotherapy is paving the way for a new era in cancer treatment, and therapeutic cancer vaccination is an area of interest. Vaccine targets include tumor-associated antigens and tumor-specific antigens. Immune responses differ in different vaccine delivery platforms. Next-generation sequencing technologies and computational analysis have recently made personalized vaccination possible. However, only a few cases benefiting from neoantigen-based treatment have been reported in breast cancer, and more attention has been given to overexpressed antigen-based treatment, especially human epidermal growth factor 2-derived peptide vaccines. Here, we discuss recent advancements in therapeutic vaccines for breast cancer and highlight near-term opportunities for moving forward.

【 授权许可】

Unknown